Two studies evaluated the efficacy and safety of JNJ-64565111, a weekly-dose GLP-1 and glucagon receptor dual agonist, in individuals with obesity without type 2 diabetes and individuals with type 2 diabetes and obesity. Here, GLP1R is linked to obesity disorder.